FrancophonIA/ELRC3.0 huggingface dataset:
English: The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers.
Croatian: malaksalost, bol u leđima i povišene upalne markere.
English: Finger grips
Croatian: oticanje lica)
English: • cutaneous vasculitis (inflammation of the blood vessels in the skin).
Croatian:  kožni vaskulitis (upala krvnih žila kože)
English: Syringe label
Croatian: NALJEPNICA NA ŠTRCALJKI
English: Elevations in lactate dehydrogenase and alkaline phosphatase1;
Croatian: Pretrage povišena razina laktat dehidrogenaz e i alkalne fosfataze1; prolazno povišenje vrijednosti testova jetrene funkcije za ALT ili AST1
English: Injecting Pelmeg yourself
Croatian: Samostalno davanje lijeka Pelmeg
English: • if you have recently had a serious lung infection (pneumonia), fluid in the lungs (pulmonary oedema), inflammation of the lungs (interstitial lung disease) or an abnormal chest x-ray (lung infiltration)
Croatian: Pogledajte dio 4.  ako osjetite bol u gornjem lijevom dijelu trbuha ili u vrhu ramena; to može biti znak problema sa slezenom (povećanje slezene)  ako ste nedavno imali ozbiljniju infekciju pluća (upalu pluća), tekućinu u plućima (edem pluća), upalne procese u području pluća (intersticijska bolest pluća) ili neuobičajeni rendgenski nalaz pluća (plućna infiltracija)  ako znate da
English: What Pelmeg is and what it is used for What you need to know before you use Pelmeg How to use Pelmeg
Croatian: Sadržaj pakiranja i druge informacije Što je Pelmeg i za što se koristi
English: There were no adverse effects observed in offspring from pregnant rats given pegfilgrastim subcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryo loss) at cumulative doses approximately 4 times the recommended human dose, which were not seen when pregnant rabbits were exposed to the recommended human dose.
Croatian: U potomstvu skotnih ženki štakora kojima je supkutano primijenjen pegfilgrastim nisu primijećene nuspojave, ali se pokazalo da je pegfilgrastim u kunića uzrokovao embrionalnu/fetalnu toksičnost
English: Uncommon elevations in liver function tests (LFTs) for ALT (alanine aminotransferase) or AST (aspartate aminotransferase), have been observed in patients after receiving pegfilgrastim following cytotoxic chemotherapy.
Croatian: Manje su često u bolesnika koji su nakon citotoksične kemoterapije primili pegfilgrastim zabilježeni slučajevi povišenja vrijednosti testova jetrene funkcije za ALT (alanin aminotransferaze) ili AST (aspartat aminotransferaze).
English: SC
Croatian: G-CSF
English: • if you have any of the following or combination of the following side effects: swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness These could be symptoms of condition called “Capillary Leak Syndrome” which causes blood to leak from the small blood vessels into your body.
Croatian:  ako imate znakove jedne od sljedećih ili kombinacije sljedećih nuspojava: oticanje ili podbuhlost, što može biti povezano s rjeđom učestalošću mokrenja, otežano disanje, oticanje trbuha i osjećaj punoće, te opći osjećaj umora
English: Metabolism and nutrition disorders
Croatian: Poremećaji metabolizma i prehrane povišena razina mokraćne kiseline
English: 6.6 Special precautions for disposal and other handling Before administration, Pelmeg solution should be inspected visually for particulate matter.
Croatian: Prije primjene potrebno je provjeriti sadrži li otopina Pelmega vidljive čestice.
English: Tel: +43 (0)1 523 25 05-0 info@mundipharma.at
Croatian: Tel: + 31 (0)33 450 82 70 info@mundipharma.nl
English: Respiratory, thoracic and mediastinal disorders
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja akutni respiratorni distres sindrom2;
English: Blood and lymphatic system disorders
Croatian: Poremećaji bubrega i mokraćnog sustava glomerulonefritis2
English: Injection site pain,
Croatian: OBLIK Otopina za injekciju.
English: This can be a sign of Acute Respiratory Distress Syndrome (ARDS)
Croatian: Manje su često ovi slučajevi rezultirali respiratornim zatajenjem ili sindromom akutnog respiratornog distresa
English: PharmaKorell GmbH Marie-Curie-Str. 8 79539 Loerrach Germany
Croatian: 79539 Loerrach
English: “SNAP”
Croatian: Pelmeg.
English: Syringe label Syringe barrel
Croatian: Hvatište za prste Naljepnica na štrcaljki
English: Thrombocytope nia1
Croatian: Konc. pegfi lgrastima ABN
English: In a phase II (n = 37) multicentre, randomised, open-label study of paediatric sarcoma patients receiving 100 μg/kg pegfilgrastim following cycle 1 of vincristine, doxorubicin and cyclophosphamide (VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils < 0.5 × 109) was observed in younger children aged 0-5 years (8.9 days) compared to older children aged 6-11 years and 12-21 years (6 days and 3.7 days, respectively) and adults.
Croatian: U fazi II (n = 37) multicentričnog, randomiziranog, otvorenog ispitivanja u pedijatrijskih bolesnika sa sarkomom koji su primali 100 μg/kg pegfilgrastima nakon 1. ciklusa kemoterapije vinkristinom,
English: This summary was last updated in 07-2015.
Croatian: Sažetak je posljednji put ažuriran u 07.2015.
English: The virus needs protease to make more viruses.
Croatian: Virusu je potrebna proteaza kako bi stvarao nove viruse.
English: It must also not be taken by patients taking certain medicines because of the possibility of interactions which could be harmful.
Croatian: Ne smiju ga uzimati bolesnici koji uzimaju određene lijekove jer postoji mogućnost interakcija koje mogu biti štetne.
English: Evotaz must not be taken by patients who have moderately or severely reduced liver function.
Croatian: Evotaz ne smiju uzimati bolesnici koji imaju umjereno ili ozbiljno smanjenje funkcije jetre.
English: The medicine is for use only in patients whose infection is not expected to be resistant to atazanavir.
Croatian: Lijek se koristi samo u bolesnika za čiju se infekciju ne očekuje da će biti otporna na atazanavir.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Evotaz on 13 July 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Evotaz na snazi u Europskoj uniji od 13. srpnja 2015.
English: The main measure of effectiveness was the proportion of patients in whom the HIV-1 count in the blood (known as viral load) was reduced to less than 50 copies/ml after 48 weeks of treatment.
Croatian: Glavna mjera djelotvornosti bio je udio bolesnika u kojih je broj virusa HIV-1 u krvi (poznat pod nazivom virusno opterećenje) bio smanjen na manje od 50 kopija/ml nakon 48 tjedana terapije.
English: Overall, 85% of patients (293 out of 344) treated with atazanavir and cobicistat achieved this reduction.
Croatian: Ukupno 85 % bolesnika (293 od 344) liječenih atazanavirom i kobicistatom postiglo je takvo smanjenje.
English: Other information about Evotaz
Croatian: Ostale informacije o lijeku Evotaz
English: It does not cure HIV infection, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS.
Croatian: Ne liječi infekcije HIV-om, no može odgoditi oštećenje imunosnog sustava, te spriječiti razvijanje infekcija i bolesti povezanih s AIDS-om.
English: What is Evotaz and what is it used for?
Croatian: Što je Evotaz i za što se koristi?
English: When the enzyme is blocked, the virus cannot reproduce itself and its spread in the body slows down.
Croatian: Kada se enzim inhibira, virus se ne može samostalno reproducirati i njegovo se širenje u tijelu usporava.
English: This was comparable to a reduction in 87% of patients (304 of 348) treated with atazanavir and ritonavir.
Croatian: To je usporedivo sa smanjenjem u 87 % bolesnika (304 od 348) liječenih atazanavirom i ritonavirom.
English: The full EPAR and risk management plan summary for Evotaz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za Evotaz kao i sažetak plana upravljanja rizikom za lijek Evotaz nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Evotaz?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Evotaz?
English: Atazanavir is a protease inhibitor.
Croatian: Atazanavir je inhibitor proteaze.
English: This is a summary of the European public assessment report (EPAR) for Evotaz.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Evotaz.
English: Why is Evotaz approved?
Croatian: Zašto je Evotaz odobren?
English: Evotaz's adverse effects were similar to those that occur with the individual medicines.
Croatian: Nuspojave lijeka Evotaz bile su slične onima koje nastupaju s pojedinačnim lijekovima.
English: A risk management plan has been developed to ensure that Evotaz is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Evotaz.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Evotaz's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Evotaz nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: Evotaz is an antiviral medicine used in combination with other medicines to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Croatian: Evotaz je antivirusni lijek koji se koristi u kombinaciji s drugim lijekovima za liječenje bolesnika zaraženih virusom humane imunodeficijencije tipa 1 (HIV-1), virusom koji uzrokuje sindrom stečene imunodeficijencije (AIDS).
English: Evotaz is available as tablets that contain 300 mg of atazanavir and 150 mg of cobicistat.
Croatian: Evotaz je dostupan kao tablete koje sadrže 300 mg atazanavira i 150 mg kobicistata.
English: What are the risks associated with Evotaz?
Croatian: Koji su rizici povezani s lijekom Evotaz?
English: The most common side effects with Evotaz (which may affect more than 1 in 10 people) are jaundice, which may show as yellow discoloration of the eye, and nausea (feeling sick).
Croatian: Najčešće nuspojave lijeka Evotaz (mogu se javiti u više od 1 na 10 osoba) su žutica, koja se manifestira kao žutilo očiju, i mučnina (osjećaj slabosti).
English: It is not intended to provide practical advice on how to use Evotaz.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Evotaz.
English: This therefore boosts atazanavir's antiviral effect.
Croatian: Time se potencira antivirusno djelovanje atazanavira.
English: In addition, the use of atazanavir with cobicistat has been evaluated in one main study in 698 HIV patients who had not been treated previously.
Croatian: Nadalje, primjena atazanavira s kobicistatom ocijenjena je u jednom glavnom ispitivanju u 698 bolesnika oboljelih od HIV-a koji prethodno nisu liječeni.
English: Evotaz atazanavir / cobicistat
Croatian: Evotaz atazanavir / kobicistat
English: Cobicistat increases the level of atazanavir in the blood by slowing its breakdown.
Croatian: Kobicistat povećava koncentraciju atazanavira u krvi tako što usporava njegovu razgradnju.
English: Combining atazanavir and cobicistat in a single tablet has the potential of simplifying the dosing regimen.
Croatian: Kombiniranje atazanavira i kobicistata u jednoj tableti može pojednostaviti režim doziranja.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Evotaz, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Evotaz nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Evotaz can only be obtained with a prescription and treatment should be started by a doctor who is experienced in managing HIV infection.
Croatian: Evotaz se izdaje samo na liječnički recept, a liječenje treba nadzirati liječnik iskusan u upravljanju infekcijama HIV-om.
English: Atazanavir and cobicistat were compared with atazanavir and ritonavir; all patients also received the HIV medicines emtricitabine and tenofovir disoproxil.
Croatian: Atazanavir i kobicistat uspoređeni su s atazanavirom i ritonavirom; svi bolesnici su također primili lijekove protiv HIV-a emtricitabin i tenofovir disoproksil.
English: For more information about treatment with Evotaz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Evotaz pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Evotaz, taken with other HIV medicines, reduces HIV in the blood and keeps the virus at a low level.
Croatian: Evotaz, u kombinaciji s drugim lijekovima protiv HIV-a, smanjuje količinu HIV-a u krvi i održava nisku koncentraciju virusa.
English: Both active substances have already been shown to be effective and Evotaz may be a useful substitute for atazanavir accompanied by ritonavir as a booster.
Croatian: Utvrđena je djelotvornost obiju djelatnih tvari, a Evotaz može biti korisna zamjena za atazanavir koji se primjenjuje s ritonavirom kao boosterom.
English: Because atazanavir and cobicistat have both previously been shown to be effective and are authorised for use in the treatment of HIV infection, studies were mainly carried out to show that Evotaz produced similar levels of atazanavir in the blood to the two active substances given separately, and to atazanavir given with a different booster medicine, ritonavir (an established combination).
Croatian: Budući da je već utvrđeno kako su atazanavir i kobicistat djelotvorni te su odobreni za primjenu u terapiji protiv infekcija HIV-om, ispitivanja su uglavnom provedena kako bi se dokazalo da Evotaz proizvodi slične koncentracije atazanavira u krvi kao i dvije djelatne tvari ako se primjenjuju zasebno, te kao atazanavir primijenjen s drugim booster lijekom, ritonavirom (utvrđena kombinacija).
English: How does Evotaz work?
Croatian: Kako djeluje Evotaz?
English: The active substances in Evotaz are already available in the EU as individual medicines: atazanavir is available as Reyataz and cobicistat as Tybost.
Croatian: Djelatne tvari u lijeku Evotaz već su dostupne unutar EU-a u pojedinačnim lijekovima: atazanavir je dostupan kao Reyataz, a kobicistat kao Tybost.
English: For practical information about using Evotaz, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Evotaz bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: What benefits of Evotaz have been shown in studies?
Croatian: Koje su koristi lijeka Evotaz utvrđene u ispitivanjima?
English: It blocks an HIV enzyme called protease from working.
Croatian: Inhibira djelovanje enzima HIV-a naziva proteaza.
English: Evotaz contains two active substances: atazanavir and cobicistat.
Croatian: Evotaz sadrži dvije djelatne tvari: atazanavir i kobicistat.
English: Evotaz contains the active substances atazanavir and cobicistat.
Croatian: Evotaz sadrži djelatne tvari atazanavir i kobicistat.
English: How is Evotaz used?
Croatian: Kako se Evotaz koristi?
English: For the full list of all side effects reported with Evotaz, see the package leaflet.
Croatian: Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Evotaz potražite u uputi o lijeku.
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled syringes (multipack)
Croatian: 1 ml (150 mg/ml) 6 (3 x 2) napunjenih štrcaljki (višestruko pakiranje)
English: 1 ml (150 mg/ml) 6 (3 x 2) pre-filled pens (multipack)
Croatian: 1 ml (150 mg/ml) 6 (3 x 2) napunjenih brizgalica (višestruko pakiranje)
English: 1 ml (150 mg/ml) 1 pre-filled pen
Croatian: 1 ml (150 mg/ml) 1 napunjena brizgalica
English: 1 ml (150 mg/ml) 2 pre-filled pens
Croatian: 1 ml (150 mg/ml) 2 napunjene brizgalice
English: 1 ml (150 mg/ml) 1 pre-filled syringe
Croatian: 1 ml (150 mg/ml) 1 napunjena štrcaljka
English: The full EPAR and risk management plan summary for Kovaltry can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Kovaltry dostupan je na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Kovaltry octocog alfa
Croatian: Kovaltry oktokog alfa
English: Other information about Kovaltry
Croatian: Ostale informacije o lijeku Kovaltry
English: Why is Kovaltry approved?
Croatian: Zašto je Kovaltry odobren?
English: What is Kovaltry and what is it used for?
Croatian: Što je Kovaltry i za što se koristi?
English: It is not intended to provide practical advice on how to use Kovaltry.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Kovaltry.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Kovaltry's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Kovaltry nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: What measures are being taken to ensure the safe and effective use of Kovaltry?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kovaltry?
English: About 70% of the bleeding events that occurred were managed with a single injection of Kovaltry, and about another 15% responded to a second injection; the response was considered good or excellent in around 80% of cases.
Croatian: Oko 70 % epizoda krvarenja zaustavljeno je jednom injekcijom lijeka Kovaltry, a otprilike dodatnih 15 % reagiralo je na drugu injekciju; djelovanje lijeka u oko 80 %slučajeva smatralo se dobrim ili izvrsnim.
English: Hypersensitivity (allergic) reactions are uncommon with Kovaltry, affecting from 1 patient in 1,000 to less than 1 patient in 100.
Croatian: Reakcije preosjetljivosti (alergijske reakcije) nisu česte pri primjeni lijeka Kovaltry, mogu se javiti od 1 na 1 000 bolesnika do manje od 1 na 100 bolesnika.
English: This is a summary of the European public assessment report (EPAR) for Kovaltry.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Kovaltry.
English: The active substance in Kovaltry, octocog alfa, works in the body in the same way as human factor VIII.
Croatian: Djelatna tvar lijeka Kovaltry, oktokog alfa, djeluje u tijelu na isti način kao ljudski faktor VIII.
English: Data from a supportive study also confirmed the benefits of preventative treatment with Kovaltry in reducing the number of bleeds.
Croatian: Podaci popratnog ispitivanja također su potvrdili koristi preventivnog liječenja lijekom Kovaltry u smanjenju broja krvarenja.
English: A risk management plan has been developed to ensure that Kovaltry is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Kovaltry.
English: What are the risks associated with Kovaltry?
Croatian: Koji su rizici povezani s lijekom Kovaltry?
English: Kovaltry is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of a clotting protein called factor VIII).
Croatian: Kovaltry je lijek koji se koristi za liječenje i sprečavanje krvarenja u bolesnika s hemofilijom A (nasljednim poremećajem krvarenja prouzročenim manjkom proteina za zgrušavanje pod nazivom faktor VIII).
English: Kovaltry can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.
Croatian: Kovaltry se izdaje samo na liječnički recept te se liječenje mora provoditi pod nadzorom liječnika s iskustvom u liječenju hemofilije.
English: Kovaltry has been shown to be effective in both preventing and treating bleeds, including managing blood loss during surgery, and can be used in all age groups.
Croatian: Lijek Kovaltry pokazao se učinkovitim u sprečavanju i liječenju krvarenja, uključujući upravljanje gubitkom krvi tijekom kirurškog zahvata te ga mogu koristiti sve dobne skupine.
English: The effectiveness of Kovaltry in preventing and treating bleeding has been shown in a main study involving 62 patients aged 12 years or older with severe haemophilia A who were previously treated with other factor VIII products.
Croatian: Djelotvornost lijeka Kovaltry u sprečavanju i liječenju krvarenja dokazana je u glavnom ispitivanju koje je uključivalo 62 bolesnika u dobi od 12 ili više godina s teškom hemofilijom A, koji su prethodno liječeni drugim lijekovima koji sadrže faktor VIII.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kovaltry, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetak opisa svojstava lijeka kao i u uputi o lijeku za lijek Kovaltry nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Kovaltry is available as a powder and solvent used to make a solution for injection.
Croatian: Kovaltry je dostupan kao prašak i otapalo koji se zajedno miješaju kako bi se dobila otopina za injekciju.
English: The dose and frequency of the injections depend on whether Kovaltry is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.
Croatian: Doza i učestalost ubrizgavanja injekcijom ovise o tome koristi li se Kovaltry za liječenje ili sprečavanje krvarenja te o težini manjka faktora VIII u bolesnika, količini i mjestu krvarenja te stanju i težini bolesnika.
English: A second study involved 51 children under 12 years of age previously treated with other factor VIII products, who also had 3.8 bleeds per year on average during treatment with Kovaltry (mostly related to injuries).
Croatian: U drugo ispitivanje bilo je uključeno 51 dijete u dobi ispod 12 godina prethodno liječeno drugim lijekovima koji sadrže faktor VIII, a u kojih je tijekom liječenja lijekom Kovaltry došlo do krvarenja u prosjeku 3,8 puta godišnje (uglavnom zbog ozljeda).
English: In addition, the company that markets Kovaltry will complete studies to investigate the safety and efficacy of the medicine in patients who have not previously been treated with other factor VIII products, and to provide further evidence of the safety and efficacy of long-term treatment with Kovaltry in children.
Croatian: Nadalje, tvrtka koja lijek Kovaltry stavlja u promet dovršit će ispitivanja kako bi se istražila sigurnost i djelotvornost lijeka u bolesnika koji nisu prethodno liječeni drugim lijekovima koji sadrže faktor VIII te kako bi se omogućili dodatni podaci o sigurnosti i djelotvornosti dugotrajnog liječenja lijekom Kovaltry u djece.
English: For more information about treatment with Kovaltry, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Kovaltry pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: How does Kovaltry work?
Croatian: Kako djeluje Kovaltry?
English: What benefits of Kovaltry have been shown in studies?
Croatian: Koje su koristi lijeka Kovaltry utvrđene u ispitivanjima?
English: How is Kovaltry used?
Croatian: Kako se Kovaltry koristi?